Aspire Biopharma Announces Material Agreement & Equity Sales
Ticker: ASBPW · Form: 8-K · Filed: Feb 20, 2025 · CIK: 1847345
| Field | Detail |
|---|---|
| Company | Aspire Biopharma Holdings, INC. (ASBPW) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Aspire Biopharma entered a material agreement, took on debt, and sold stock on Feb 13th.
AI Summary
Aspire Biopharma Holdings, Inc. announced on February 13, 2025, the entry into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. This filing also includes a Regulation FD disclosure and financial statements.
Why It Matters
This 8-K filing indicates significant corporate actions including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Aspire Biopharma Holdings, Inc. (company) — Filer
- PowerUp Acquisition Corp. (company) — Former Company Name
- 20250213 (date) — Date of earliest event reported
- 0001493152-25-007732 (accession_number) — Filing Accession Number
FAQ
What type of material definitive agreement did Aspire Biopharma Holdings, Inc. enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 13, 2025.
What are the key items reported in this 8-K filing?
The key items reported include entry into a material definitive agreement, creation of a direct financial obligation, unregistered sales of equity securities, Regulation FD disclosure, and financial statements.
What was Aspire Biopharma Holdings, Inc. formerly known as?
Aspire Biopharma Holdings, Inc. was formerly known as PowerUp Acquisition Corp.
What is the SIC code for Aspire Biopharma Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).